Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

FDA Warned of Avandia Risks Years Ago

Doctor alerted agency to cardiovascular concerns in 2000

By Sam Gale Rosen, Newser Staff

Posted May 24, 2007 1:56 PM CDT

(Newser) – A diabetes doctor warned the FDA of heart risks posed by the diabetes drug Avandia seven years ago, the New York Times reports. The same concerns raised by Dr. John Buse in a 2000 letter were reiterated in a study published by cardiologist Steven Nissen... Read full story »

COMMENTS

Read the comment policy

You need to Log in to Newser to comment. Don't have an account yet? Sign up now!

There are no comments

A snapshot of the day's best news stories.

View Larger Grid

All Today Yesterday Pick a Date

What's Popular Now on Facebook

Cops Shoot Naked Guy Eating Man's Face on Highway

Japanese Artist Serves Up Own Cooked Genitals

New York Times (Source Grid »)

health • diabetes • GlaxoSmithKline • Avandia • pharma • John Buse

More Newser Stories

Diabetes Drug Ups Heart Risk

New study documents dangers of Avandia, but company nixes recall

(NEWSER) - A popular diabetes drug may increase heart attack risks, a study reported in the New England Journal of Medicine concludes. Patients who took Avandia, which treats Type 2 diabetes, were 43% more likely to have a heart attack than those who took a placebo, the Cleveland Clinic study found. More»

FDA Panel Votes to Keep Avandia on Shelves

Controversial diabetes drug still faces heart-attack link

(NEWSER) - An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes drugs. More»

Controversy Rages Over Diabetes Drug's Heart Risks

FDA official says superiors ordered her to back off serious warning

(NEWSER) - Troubling questions about the diabetes drug Avandia persisted yesterday as an FDA official revealed that she was barred from recommending a critical warning about the medication, the Times reports. In the run-up to congressional hearings that began today, manufacturer GlaxoSmithKline rushed to disseminate interim clinical findings in hopes of blunting the controversy. More»

Glaxo Stems Stock Slide Over Avandia

Medical chief rebuts findings on heart risks; claims comparable to other drugs

(NEWSER) - Glaxo shares pulled out of a tailspin after the pharma giant defended its second biggest selling drug, Avandia, against claims that it triggers heart attacks. A sharply worded letter from the company's chief medical officer on the website of medical journal The Lancet pointed out that the increased incidence of heart attacks among Avandia patients—0.6%—was still very small. More»

FDA Panel: Keep Avandia on Market

But it may get warning label on heart risks

(AP) - A majority of federal health experts has voted to keep the controversial diabetes pill Avandia on the market despite evidence that it increases the risk of heart attack. A panel of Food and Drug Administration advisers voted 20-12 against withdrawing GlaxoSmithKline's once-blockbuster drug. The agency is not required to follow the group's advice, but it usually follows the advice of its advisory committees. More»

NEWS FROM OUR PARTNERS

What is Newser?

Face it: there's too much news. At Newser, we choose the most thought-provoking and entertaining stories from hundreds of US and international sources and reduce them to a headline, picture, and two paragraphs. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »

Partnering with: Slate

View Newser on the mobile website

FDA Warned of Avandia Risks Years Ago

Doctor alerted agency to cardiovascular concerns in 2000

health • diabetes • GlaxoSmithKline • Avandia • pharma • John Buse

MOST POPULAR STORIES

[ By Views ]

[ By Comments ]

More Newser Stories

Diabetes Drug Ups Heart Risk

New study documents dangers of Avandia, but company nixes recall

FDA Panel Votes to Keep Avandia on Shelves

Controversial diabetes drug still faces heart-attack link

Controversy Rages Over Diabetes Drug's Heart Risks

FDA official says superiors ordered her to back off serious warning

Glaxo Stems Stock Slide Over Avandia

Medical chief rebuts findings on heart risks; claims comparable to other drugs

FDA Panel: Keep Avandia on Market

But it may get warning label on heart risks

About Us

Site

Community

Site Maps

Tools

More News

What is Newser?